Even if microbiota-relateds treatments are quite recent in the therapeutical field, at least 2,400 clinical trials were launched in 2018! Gut, skin and oncology microbiota will be definitively be the hot topic in the next 10 years. Of course, we are heavily working in the field, with a focus on skin with the reconstruction of a 3D “in vitro” skin model with BIOMIMESYS® in a HCS context.
As explained in this article, an important step will be also the adaptation of EU drug regulation to make the commercialization of such treatments easier.
The companies will propose EU regulatory changes that make it easier to commercialize treatments based on targeting a patient’s microbiome bacteria. Microbiome-based treatments form a young field in the industry, with big potential to treat diseases such as inflammatory bowel disease and even cancer.